Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

54.51 -0.57 (-1.03%)
Streaming Delayed Price Updated: 11:37 AM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
34 35 Next >
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week ↗
These companies could stand out thanks to game-changing technology. 
Via The Motley Fool
News headline image
2 Red Flags for Bluebird Bio Stock ↗
The biotech's struggles may continue. 
Via The Motley Fool
News headline image
3 Cathie Wood Stocks to Start Off Your New Year Right ↗
The following stocks could deliver big gains over time. 
Via The Motley Fool
News headline image
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
News headline image
The Ultimate Growth Stock to Buy With $1,000 Right Now ↗
The stock, trading for about $60, has plenty of room to run. 
Via The Motley Fool
News headline image
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Could CRISPR Therapeutics Stock Help You Become a Millionaire? ↗
There are plenty of reasons to be optimistic about CRISPR's future. 
Via The Motley Fool
News headline image
5 Innovative Stocks That Could Score a Win for Your Portfolio in 2024 ↗
You'll find exciting innovators across industries. 
Via The Motley Fool
News headline image
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
News headline image
2 Biotech Stocks With Huge Catalysts in 2024 ↗
Important clinical-trial readouts on the way could send these stocks soaring in early 2024. 
Via The Motley Fool
News headline image
Gen Z’s Top Picks for 2024: 7 Trending Stocks Among Young Investors ↗
Gen Z stocks include companies the generation prefers to invest in while capturing the emerging economic force they represent. 
Via InvestorPlace
News headline image
Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics ↗
CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead. 
Via The Motley Fool
News headline image
3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition ↗
Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside. 
Via InvestorPlace
News headline image
Better Risky Investment: Bluebird Bio vs. Shiba Inu ↗
Few investors dare to tread where the ice is known to be very thin. 
Via The Motley Fool
News headline image
3 Biotech Stocks Set for Breakthroughs in 2024 ↗
With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks. 
Via InvestorPlace
News headline image
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal 
Via MarketBeat
News headline image
3 No-Brainer Growth Stocks to Buy for Less Than $100 ↗
These businesses have promising futures and make for great investment options today. 
Via The Motley Fool
News headline image
1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024 ↗
Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name. 
Via The Motley Fool
News headline image
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics ↗
Curing rare inherited illnesses could be a lucrative business model. 
Via The Motley Fool
News headline image
2023 in Review: Nvidia, Interest Rates, Taylor Swift ↗
And a little bit of real estate insight. 
Via The Motley Fool
News headline image
3 Stocks That Could Be Monster Winners in 2024 ↗
Don't be surprised if these three stocks take off in the new year. 
Via The Motley Fool
News headline image
AI and Automation Leaders for 2024: 7 Stocks to Stay Ahead of the Robot Uprising ↗
With the robotics revolution taking over multiple industries, investors have options. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
CRISPR Therapeutics sets sights on gene-editing cures for disease
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for 
Via MarketBeat
News headline image
3 Top Stocks to Buy Hand Over Fist Before the End of 2023 ↗
These are ideal stocks to buy sooner rather than later. 
Via The Motley Fool
News headline image
3 Healthcare Technology Stocks to Improve Lives in 2024 ↗
Healthcare technology is one of 2024's top investment trends, and investors looking for long-term upside should check out these top stocks. 
Via InvestorPlace
News headline image
1 Green Flag and 1 Red Flag for Bluebird Bio Stock ↗
The stock has been in the news lately. 
Via The Motley Fool
News headline image
Cathie Wood Predicts Deflation In 2024, More AI And Tech Optimism — And Rate Cuts ↗
Cathie Wood believes deflation in 2024, aggressive rate cuts and technological progress will drive expansion. 
Via Benzinga
Topics Artificial Intelligence Economy
News headline image
3 Money-Saving Tricks for Investing in Biotech Stocks in 2024 ↗
Doing a little math and doing a little extra research can make a big difference. 
Via The Motley Fool
News headline image
I'm Begging You to Buy Stocks Before January -- Here's Why ↗
Some studies have shown a pattern of market gains in the month of January. 
Via The Motley Fool
News headline image
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock? ↗
The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction. 
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.